{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:23:33Z","timestamp":1737609813760,"version":"3.33.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1975,4,1]],"date-time":"1975-04-01T00:00:00Z","timestamp":165542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1975,4,1]],"date-time":"1975-04-01T00:00:00Z","timestamp":165542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1975,4]]},"DOI":"10.1136\/ard.34.2.196-b","type":"journal-article","created":{"date-parts":[[2008,7,28]],"date-time":"2008-07-28T23:49:46Z","timestamp":1217288986000},"page":"196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proceedings: Defective cellular immunity in juvenile rheumatoid arthritis."],"prefix":"10.1016","volume":"34","author":[{"given":"J","family":"Jennings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"ref_1","first-page":"636","article-title":"Atlas of Standard Radiographs of Arthritis'","volume":"1","author":"KEELE, K.D.","year":"1963","unstructured":"Atlas of Standard Radiographs of Arthritis'. (1963) Oxford KEELE, K. D. (1954) Lancet, 1, 636"},{"article-title":"An unusual opportunity for such a study was provided by a total of 580 patient-weeks of chrysotherapy adjusted to individual 'tolerance', i.e. up to mild side-effects in everyone, in search of maximal efficacy","year":"1973","key":"ref_2","unstructured":"An unusual opportunity for such a study was provided by a total of 580 patient-weeks of chrysotherapy adjusted to individual 'tolerance', i.e. up to mild side-effects in everyone, in search of maximal efficacy (Lorber and others, 1973)."},{"article-title":"Twenty-four patients with 'definite' or 'classical' RA, unresponsive to or intolerant of oral anti-inflammatory medication (including corticosteroids in 15) were treated. Clinical and laboratory parameters of inflammatory disease activity and of (potential) toxicity were monitored weekly, as well as 7th day serum gold levels (by atomic absorption against a weighed gold standard), as previously described in detail","year":"1973","key":"ref_3","unstructured":"Twenty-four patients with 'definite' or 'classical' RA, unresponsive to or intolerant of oral anti-inflammatory medication (including corticosteroids in 15) were treated. Clinical and laboratory parameters of inflammatory disease activity and of (potential) toxicity were monitored weekly, as well as 7th day serum gold levels (by atomic absorption against a weighed gold standard), as previously described in detail (De Bosset and Bitter, 1973)."},{"key":"ref_4","article-title":"But at variance with a recent investigation (Co-operating clinics of","volume-title":"a certain (not quite) significant trend emerged towards an increased anti-inflammatory effect of gold in patients with high initial joint scores: in addition there were parallel trends towards steep decreases in remission rate, 'barely tolerated' weekly dose and serum gold level between the ages of 45 and 65 years. This suggestion of a narrow therapeutic margin above the age of 60 could question the indications for chrysotherapy in the elderly","author":"A, A.R.","year":"1973","unstructured":"But at variance with a recent investigation (Co-operating clinics of the A.R.A., 1973) a certain (not quite) significant trend emerged towards an increased anti-inflammatory effect of gold in patients with high initial joint scores: in addition there were parallel trends towards steep decreases in remission rate, 'barely tolerated' weekly dose and serum gold level between the ages of 45 and 65 years. This suggestion of a narrow therapeutic margin above the age of 60 could question the indications for chrysotherapy in the elderly.","edition":"the"},{"key":"ref_5","unstructured":"Our current hypothesis is that disturbances in the proportion of T cells in the peripheral blood and defects in T cell function pin-point defects in cellular immunity, sufficient to facilitate the spread of infective agents to the joints. This would account for the association of polyarthritis with the group characterized by anomalous T cell behaviour.","article-title":"Our current hypothesis is that disturbances in the proportion of T cells in the peripheral blood and defects in T cell function pin-point defects in cellular immunity, sufficient to facilitate the spread of infective agents to the joints. This would account for the association of polyarthritis with the group characterized by anomalous T cell behaviour"},{"key":"ref_6","first-page":"1153","article-title":"Schweiz","volume":"103","author":"BOSSET, D.E.; P.; BtTTER, T.","year":"1973","unstructured":"DE BOSSET, P., and BtTTER, T. (1973) Schweiz. med. Wschr., 103, 1153 LORBER, A. et al. (1973) Ann. rheum. Dis., 33.","journal-title":"med. Wschr"},{"key":"ref_7","first-page":"353","article-title":"Arthr","volume":"16","author":"clinics of the A. R. A, Co-operating","year":"1973","unstructured":"Co-operating clinics of the A.R.A. (1973) Arthr. and Rheumn., 16, 353","journal-title":"and Rheumn"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724410832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724410832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.34.2.196-b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:00:03Z","timestamp":1737547203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724410832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1975,4]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1975,4]]}},"alternative-id":["S0003496724410832"],"URL":"https:\/\/doi.org\/10.1136\/ard.34.2.196-b","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[1975,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings: Defective cellular immunity in juvenile rheumatoid arthritis.","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.34.2.196-b","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1975 \u00a9 THE AUTHORS. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology, EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}